Session Information
-
WCLC 2020
2020 World Conference on Lung Cancer
Conference Program for the 2020 World Conference on Lung Cancer in Singapore
Presentation Date(s):- January 28 - 31, 2021
- Total Presentations: 1597
All times listed are in Singapore time (GMT+8)
PL - Plenary
PS - Presidential Symposium
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
IS - Industry Symposium
JICC - Joint IASLC-CAALC-CSCO Session
January 28 Thu
Jan 28 Friday
January 29 Fri
Jan 29 Saturday
January 30 Sat
Jan 30 Sunday
January 31 Sun
Jan 31
-
+
IS07 - Industry Symposium Sponsored by Roche: Expert Perspectives on the Management of Lung Cancer
- 16:45 - 17:45
- 1/28/2021
- Location: Industry Symposia Auditorium (via Industry Hub)
- Not for CME Credit
- Type: Industry Symposium
- Track:
-
+
IS07.02 - Future Directions for Cancer Immunotherapy: Resectable NSCLC and Novel Combinations in Lung Cancer
17:15 - 17:45 | Presenter: Ross Soo, Solange Peters, Martin Reck
- Abstract
No abstract available for this presentation
-
+
FP13 - Immunotherapy (Phase II/III Trials)
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Type: Posters (Featured)
- Track: Immunotherapy (Phase II/III Trials)
-
+
FP13.02 - Pembrolizumab + Pemetrexed-Platinum vs Pemetrexed-Platinum for Metastatic NSCLC: 4-Year Follow-up From KEYNOTE-189
00:00 - 00:00 | Presenter: Jhanelle Elaine Gray
- Abstract
Loading...
-
+
FP14 - Targeted Therapy - Clinically Focused
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Type: Posters (Featured)
- Track: Targeted Therapy - Clinically Focused
-
+
FP14.12 - Quality of Life and Subgroup Analysis in a Phase 3 Randomized Study of Ensartinib vs Crizotinib in ALK–Positive NSCLC Patients: eXalt3.
00:00 - 00:00 | Presenter: Yi-long Wu
- Abstract
Loading...
-
+
P01 - Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
-
+
P01.21 - ANSELMA: Antiangiogenic Second Line Lung Cancer Meta-Analysis on Individual Patient Data in Non-Small Cell Lung Cancer, Again Relevant in ICI Era
00:00 - 00:00 | Presenter: Jordi Remon
- Abstract
Loading...
-
+
P75 - Immunotherapy (Phase II/III Trials) - Misc. Topics
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P75.04 - Advanced Lung Cancer Inflammation Index (ALI), Neutrophil-to-Lymphocyte Ratio (NLR), and PD-(L)1 Inhibitor Efficacy in NSCLC
00:00 - 00:00 | Presenter: Petros Christopoulos
- Abstract
Loading...
-
+
P77 - Immunotherapy (Phase II/III Trials) - Combining Different Immunotherapeutic Approaches
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P77.04 - PROPEL: A Phase 1/2 Trial of Bempegaldesleukin (NKTR-214) Plus Pembrolizumab in Lung Cancer and other Advanced Solid Tumors
00:00 - 00:00 | Presenter: David R. Spigel
- Abstract
Loading...
-
+
OA02 - Updates in Locally Advanced NSCLC
- 09:15 - 10:15
- 1/29/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Locoregional and Oligometastatic Disease
-
+
OA02.03 - Pembrolizumab Plus Platinum Chemotherapy and Radiotherapy in Unresectable, Locally Advanced, Stage III NSCLC: KEYNOTE-799
09:15 - 09:25 | Presenter: Martin Reck
- Abstract
Loading...
-
+
PS01 - Presidential Symposium (Japanese, Mandarin, Spanish Translation Available)
- 07:00 - 09:00
- 1/30/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Plenary
- Track: N.A.
-
+
PS01.04 - International Tailored Chemotherapy Adjuvant Trial : ITACA Trial. Final Results
07:20 - 07:30 | Presenter: Silvia Novello
- Abstract
Loading... -
+
PS01.09 - Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo as 1L Therapy for Metastatic NSCLC of PD-L1 TPS ≥50%: KEYNOTE-598
08:08 - 08:18 | Presenter: Michael Boyer
- Abstract
Loading...
-
+
PS02 - Presidential Symposium (Re-Broadcast) (Japanese, Mandarin, Spanish Translation Available)
- 18:00 - 20:00
- 1/30/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Plenary
- Track: N.A.
-
+
PS02.04 - International Tailored Chemotherapy Adjuvant Trial : ITACA Trial. Final Results
18:20 - 18:30 | Presenter: Silvia Novello
- Abstract
Loading... -
+
PS02.09 - Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo as 1L Therapy for Metastatic NSCLC of PD-L1 TPS ≥50%: KEYNOTE-598
19:08 - 19:18 | Presenter: Michael Boyer
- Abstract
Loading...
-
+
OA11 - A Symphony of Progress
- 15:30 - 16:30
- 1/31/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Small Cell Lung Cancer/NET
-
+
OA11.06 - IMpower133: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage Small-Cell Lung Cancer
16:00 - 16:10 | Presenter: Martin Reck
- Abstract
Loading...